Ocugen

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400. 15 September 2025 -- Pennsylvania, US -- Ocugen, Inc., a pioneering biotechnology leader in gene therapies for...
11 Great Valley Parkway Malvern, PA 19355

484.328.4701